Molecular basis of Canavan disease

European Journal of Paediatric Neurology

Volumn 2, Issue 2, 1998, Pages 69-76

  Matalon, Reuben ^a   Michals Matalon, Kimberlee ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Aspartoacylase; Canavan disease; N Acetylaspartic acid; Spongy degeneration of the brain

Indexed keywords

CANAVAN DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME DEFECT; GENOTYPE; HUMAN; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; WHITE MATTER;

EID: 0031750574     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3798(98)80044-5     Document Type: Review

References (44)

1. Canavan MM. Schilder's encephalitis periaxialis diffusa. Arch Neural Psychiat 1931; 25: 299-308.
2. van Bogaert L, Bertrand I. Sur une idiote familiale avec dégénérescence spongieuse de neuraxe (note préliminaire). Acta Neurol Belg 1949; 12: 572-587.
3. Banker BQ, Victor H. Spongy degeneration of infancy. In: Goodman RH and Motulsky A (eds) Genetic Diseases Among Ashkenazi Jews. New York: Raven Press, 1979: 201-217.
4. Matalon R, Michals K, Sebasta D et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29: 463-471.
5. Kaul RK, Gao GP, Balamurugan K, Matalon R. Human aspartoacylase cDNA and mis-sense mutation in Canavan disease. Nature Genetics 1993; 5: 118-123.
6. Matalon R, Kaul R, Michals K. Carrier rate of Canavan disease among Ashkenazi Jewish individuals. Am J Hum Genet 1994; 55: A908.
7. Kaul RK, Balamurugan K, Gao GP, Matalon R. Canavan disease: Genomic organization and localization of human ASPA gene during evolution. Genomics 1994; 21: 364-370.
8. Ory-Lavollee L, Blakely RD, Coyle JT. Neurochemical and immunochemical studies on the distribution of N-acetylaspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. J Neurochem 1987; 48: 895-899.
9. Kaul R, Michals K, Casanova J, Matalon R. The role of N-acetylaspartic acid in brain metabolism and the pathogenesis in Canavan disease. Int Pediat 1991; 6: 40-43.
10. Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrand type). Acta Neuropath 1972; 20: 22-31.
11. Adornato BT, O'Brien JS, Lampert PW et al. Cerebral spongy degeneration of infancy: a biochemical and ultrastructural study of affected twins. Neurology 1972; 22: 202-210.
12. Matalon R, Michals K, Kaul R, Johnson AB. Biochemical and enzyme characterization of Canavan disease. In: Bonne-Tamir B (ed) Genetic Diversity Among Jews: Diseases and Markers at the DNA Level. New York: Oxford University Press, 1992: 140-149.
13. Luo Y, Huang K. Spongy degeneration of the CNS in infancy. Arch Neurol 1984; 41: 164-170.
14. Rushton AR, Shaywitz BA, Dumen CC et al. Computerized tomography in the diagnosis of Canavan's disease. Ann Neurol 1981; 10: 57-60.
15. Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. Am J Neurol Res 1990; 11: 805-810.
16. Matalon R, Michals K, Kaul R, Mafee M. Spongy degeneration of the brain, Canavan disease. Int Pediat 1990; 5: 121-124.
17. Grodd W, Krageloh-Mann I, Peterson D et al. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy. Lancet 1990; 336: 437-138.
18. Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR Spectroscopy in children with Canavan's disease. J Magn Reson Imaging 1996 6: 889-893.
19. Matalon R, Kaul R, Michals K. Canavan disease. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL (eds) The Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth-Heinemann 1997; 493-502.
20. Topcu M, Erde G, Saatci I et al. Clinical and magnetic resonance imaging features of L-2-hydroxyglutaric acidemia: Report of three cases in comparison to Canavan disease. J Child Neurol 1996; 11: 373-377.
21. Goutieres F, Boulloche J, Bourgeois M, Aicardi J. Leukoencephalopathy, megalencephaly, and mild clinical course. A recently individualized familial leukodystrophy. Report on five new cases. J Child Neurol 1996; 11: 439-144.
22. van der Knaap MS, Barth PG, Vrensen GF, Valk J. Histopathology of an infantile-onset spongiform leukoencephalopathy with a discrepantly mild clinical course. Acta Neuropathol 1996; 92: 206-212.
23. Mejaski-Bosnjak V, Besenski N, Brockmann K et al. Cystic leukoencephalopathy in a megalencephalic child: Clinical and magnetic resonance imaging/ magnetic resonance spectroscopy findings. Pediatr Neurol 1997; 16: 347-50.
24. Chou SM, Waisman HA. Spongy degeneration of the central nervous system, case of homocystinuria. Arch Pathol 1965; 70: 357-63.
25. Rushton DI. Spongy degeneration of the white matter of the central nervous system associated with hyperglycinuria. J Clin Pathol 1968; 21: 456-462.
26. Lisson G, Leupold D, Bechinger D, Wallesch C. CT findings in a case of deficiency of 3-hydroxy-3methylglutaryl CoA lyase. Neuroradiology 1981; 22: 99-101.
27. Walters GF. Molecular pathological aspects in spongy encephalopathies. Wien Klin Wochenschr 1982; 94: 375-376.
28. Egger J, Wayne-Williams CJ, Erdohazi M. Mitochondrial cytopathy or Leigh's syndrome? Mitochondrial abnormalities in spongiform encephalopathies. Neuropediatrics 1992; 13: 219-224.
29. Matalon R, Kaul R, Casanova J et al. Aspartoacylase deficiency: the enzyme defect in Canavan disease. J Inher Metab Dis 1989; 12: 463-471.
30. Kaul R, Gao GP, Aloya M et al. Canavan disease: Mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994; 55: 34-41.
31. Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995; 57: 1250-1252.
32. Kaul R, Gao GP, Matalon R et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 1996; 59: 95-102.
33. Shaag A, Anikster Y, Christensen E et al. The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 1995; 57: 572-580.
34. Kaul R, Gao GP, Michals K et al. A novel (cys152 > arg) missense mutation in Arab patient with Canavan disease. Hum Mutat 1995; 5: 269-271.
35. Kobayashi K, Tsujino S, Ezoe T et al. A missense mutation (I143T) in a Japanese patient with Canavan disease. Hum Mutat (in press).
36. During M. Gene therapy in New Zealand. Science (Res News). 1996 272: 467.
37. Hlum S, Seymour K, Philippart M et al. Elevated brain water in Canavan disease: Impact of a diuretic therapy. Int Soc Mag Res (in press).
38. Matalon R, Kaul R, Gao GP et al. Prenatal diagnosis for Canavan disease: The use of DNA markers. J Inher Metab Dis 1995; 18: 215-217.
39. Bennett MJ, Gibson KM, Sherwood WG et al. Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): Comparison of enzymatic and metabolite analysis. J Inher Metab Dis 1993; 16: 831-836.
40. Kelley RI. Prenatal diagnosis of Canavan disease by measurement of N-acetyl-L-aspartate in amniotic fluid. J Inher Metab Dis 1993; 16: 918-919.
41. Azzam NA, Bready JV, Vinters HV, Camcilla PA. Spontaneous spongy degeneration of the mouse brain. J Neuropath Exp Neurol 1984; 43: 118-130.
42. Hagen G, Bjerkas I. Spongy degeneration of white matter in the central nervous system of sliver foxes (Vulpes vulpes). Vet Pathol 1990; 27: 187-193.
43. Zachary JF, O'Brien CP. Spongy degeneration of the central nervous system in two canine littermates. Vet Pathol 1985; 22: 561-567.
44. Mason RW, Hartley WJ, Randall M. Spongiform generation of the white matter in a saymoyed pup. Aust Vet Pract 1979; 9: 11-13.